Forte Biosciences, Inc. (TOCA) [Rocket]

In millions, except per share items	Jun-30-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Total revenues		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]		12.2	10.5	14.8	18.6	18.2	16.3	10.0
Sales and marketing			3.4				13.4	5.7
General and administrative		8.7		7.1	5.1	4.7
Research and development		5.6	4.5	8.7	11.2	13.9	15.5	13.6
Other operating expenses		-12.2	-9.5			-27.3	-22.6	-9.3
EBITDA [+]								-14.2
EBITDA growth		16.7%	-40.0%	-61.1%	-85.0%	-66.5%	-18.0%	105.0%
Depreciation and amortization								0.0
EBIT [+]		-5.5	-5.5	-5.5	-2.5	-4.7	-9.2	-14.2
EBIT growth		16.7%	-40.1%	-61.1%	-85.2%	-66.7%	-18.3%	104.3%
Other income (expense), net [+]		-8.3	-6.8	-11.2	-17.0	-17.0	-13.7	-6.1
Other				-0.1	-0.1
Pre-tax income		-13.9	-12.3	-16.7	-19.5	-21.7	-22.9	-20.3
Income taxes		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income		-13.9	-12.3	-16.7	-19.5	-21.7	-22.9	-20.3

Basic EPS [+]		($0.84)	($0.79)	($1.16)	($1.38)	($1.58)	($1.89)	($1.79)
Growth		-46.5%	-58.2%	-35.3%	-75.2%	-79.4%	-79.2%	-91.0%
Diluted EPS [+]		($0.84)	($0.79)	($1.16)	($1.38)	($1.58)	($1.89)	($1.79)
Growth		-46.5%	-58.2%	-35.3%	-75.2%	-79.4%	-79.2%	-91.0%

Shares outstanding (basic) [+]		16.5	15.6	14.4	14.1	13.8	12.1	11.4
Growth		19.6%	28.8%	27.1%	59.5%	126.3%	153.9%	476.7%
Shares outstanding (diluted) [+]		16.5	15.6	14.4	14.1	13.8	12.1	11.4
Growth		19.6%	28.8%	27.1%	59.5%	126.3%	153.9%	476.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.